A cute spontaneous intracerebral hemorrhage (ICH) affects several million people worldwide each year, 1 resulting in a heavy burden of premature death and disability.
A cute spontaneous intracerebral hemorrhage (ICH) affects several million people worldwide each year, 1 resulting in a heavy burden of premature death and disability. 2 The cerebral injury from ICH involves several overlapping mechanisms beginning with physical disruption and mass effect from the hematoma and associated cerebral edema and later from the consequences of the toxic effects of hemoglobin breakdown products, free radicals, and inflammation. 3 Initial volume and subsequent growth of the hematoma are pivotal to determining outcome in ICH, 4 but perihematomal edema (PHE) also contributes to the risk of death and disability from raised intracranial pressure or hydrocephalus. 5, 6 Several potential time-dependent mechanisms underlie the formation of PHE 7 : an early phase (the first hours) of hydrostatic pressure and clot retraction from serum moving out of the hematoma and into surrounding cerebral tissue; and a later phase that
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involves activation of the coagulation cascade and thrombin production, and secondary toxicity from erythrocyte lysis and iron deposition. Despite its importance clinically, there is ongoing controversy as to whether PHE has independent prognostic significance in acute ICH. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] In our previous analysis of 270 patients with ICH from the pilot phase Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT1), neither the degree of growth from baseline or absolute volume at 24 hours of PHE was associated with 90-day outcomes independent of hematoma volume. 12 This result may have been because of limited statistical power to detect modest associations. We therefore investigated the prognostic significance of PHE in >1000 patients with acute ICH by combining data from INTERACT1 17 with those of the main phase INTERACT2, 18 both of which included patients with predominantly mild-moderate sized deep hemisphericlocated ICH.
Methods

Participants
INTERACT1 and INTERACT2 were international, multicenter, prospective, open, blinded end point, randomized controlled trials, as described in detail elsewhere. 17, 18 In brief, the respective studies included 404 and 2839 patients with spontaneous ICH within 6 hours of onset and elevated systolic blood pressure (SBP, 150-220 mm Hg) who were allocated to receive intensive (target SBP, <140 mm Hg within 1 hour) or guideline-recommended (target SBP, <180 mm Hg) BP-lowering treatment. Patients were excluded if they had a structural cause for the ICH, deep coma (scores, 3-5 on the Glasgow coma scale), massive hematoma with a poor prognosis, or if early surgery to evacuate the hematoma was planned. Eligible participants were randomly assigned treatment through a secure web-based system that used a minimization algorithm to ensure that the groups were balanced according to country, hospital, and time (≤4 versus >4 hours) from the onset of symptoms. Participants allocated to intensive BP lowering were to commence intravenous treatment and oral agent(s), according to prespecified treatment protocols based on locally available agents. Participants allocated to the guideline group were to receive BP treatment if their SBP was >180 mm Hg; no lower level was stipulated. All participants were to receive oral antihypertensive agents (or topical nitrates) within 7 days (or discharge from hospital if sooner), including via a nasogastric tube if required; if not contraindicated and no other drugs were specifically required, combination treatment with an angiotensin-converting enzyme inhibitor and diuretic was recommended, with the goal of achieving a SBP level of <140 mm Hg during follow-up for the prevention of recurrent stroke. The study protocols were approved by the appropriate ethics committee at each participating site, and all patients or an appropriate surrogate provided informed consent.
Procedures
Demographic and clinical characteristics were recorded at the time of enrollment, with stroke severity measured using the Glasgow coma scale and National Institutes of Health stroke scale at baseline, 24 hours, and at day 7 (or earlier on discharge from hospital). In predefined computed tomographic (CT) substudies, 1310 patients (346 INTERACT1; 964 INTERACT2) underwent a repeat CT at 24 hours using the same procedure as the baseline CT. For each CT scan, uncompressed digital CT images were collected in Digital Imaging and Communications in Medicine format on a CD-ROM identified only with the patient's unique study number. For each study, PHE volumes were calculated independently by 2 trained neurologists who were blind to clinical data, treatment, and date and sequence of scan, using computer-assisted multislice planimetric and voxel threshold techniques in MIStar (version 3.2). 19 
Statistical Analysis
Baseline demographic and risk factor variables were descriptively summarized as mean (SD) or median (interquartile range) for continuous variables and as number (%) for categorical variables. Predictors of growth in PHE volume per 5 mL (ie, threshold of visibility to the eye) >24 hours were ascertained by ANCOVA. Associations of growth in PHE and clinical outcomes were estimated in multivariable logistic regression models. A standard level of significance (P<0.05) was used, and the data were reported as odds ratios and 95% CIs. Sensitivity analyses were conducted according to different volumes of growth in PHE (1 mL, per SD, and 10 mL) and by tertiles in the distribution of time from baseline to second (24 hours) CT scan. Analyses were performed using SAS software (version 9.3).
Results
Baseline characteristics of participants of the CT substudies compared with the others are shown in Table 1 . Among the 1310 participants of CT substudies, 1138 (87%) patients had 2 CT scans available for analysis in Digital Imaging and Communications in Medicine format, as well as information on clinical outcomes at 90 days. Table 1 shows that CT substudy patients were significantly more likely to be from China, have lower Glasgow coma scale scores, and be randomized to intensive treatment. Mean-achieved SBP levels were 149 mm Hg in the intensive group, 164 mm Hg in the guideline group at 1 hour (∆15 mm Hg; 95% CI, 12-17 mm Hg; P<0.0001), and 156 mm Hg and 143 mm Hg during 1 to 24 hours (∆13 mm Hg; 95% CI, 12-15 mm Hg; P<0.0001). Median PHE volumes at baseline were 2.47 mL in the guideline group and 2.67 mL in the intensive group. Absolute growth in PHE was 4.77 mL (95% CI, 3.91-5.63) in the intensive group and 5.65 mL (95% CI, 4.81-6.48) in the guideline group (difference, 0.88 mL; 95% CI, 0.03-1.71 mL; P=0.04), after adjusting for baseline volume and location of hematoma, time from ICH onset to first CT, and trial. Table 2 shows the predictors of absolute growth in PHE volume >24 hours. Baseline variables associated with growth in univariable analysis were age, country, National Institutes of Health stroke scale score, time from ICH onset to baseline CT, baseline hematoma volume, 24-hour hematoma growth, mannitol treatment, and trial. In multivariable analysis, only time from ICH onset to baseline CT, baseline hematoma volume, 24-hour hematoma growth, intraventricular extension, and trial were independently associated with absolute growth in PHE volume. Table 3 shows the associations between absolute growth in PHE volume and clinical outcomes at 90 days, at which time, 130 (11%) patients were dead and 497 (44%) were dependent. In univariable analysis, absolute growth of PHE volume was associated with the primary poor outcome of death or dependency (odds ratio, 1.24; 95% CI, 1.12-1.37) per 5 mL increase in PHE volume. These associations remained significant after adjustment for age, sex, country of residence (China versus non-China), history of ICH, ischemic stroke, acute coronary syndrome, diabetes mellitus, current treatment of hypertension, antithrombotic use, and lipid-lowering treatment, time from ICH onset to baseline CT, admission SBP, admission glucose, high National Institutes of Health stroke scale score, lobar location of hematoma, baseline hematoma volume, 24-hour hematoma growth, intraventricular extension of the hematoma, mannitol treatment, randomized treatment, and trial (odds ratio, 1.17; 95% CI, 1.02-1.33; P=0.025). There were no significant associations of PHE growth on the separate outcomes of death or dependency. The association of PHE growth with poor outcome was consistent between the randomized treatment groups (Table I in the online-only Data Supplement), although this only remained significant in adjusted analysis for the guideline group (odds ratio, 1.33; 95% CI, 1.09-1.64; P=0.006). There was no heterogeneity in the prognostic significance of PHE across tertiles of time from baseline to the 24-hour CT scan, or according to different volumes of PHE growth (Tables II and III in the online-only Data Supplement). A 1-to 10-mL growth of PHE was associated with between a 3% to 40% higher risk of death or dependency at 90 days.
Discussion
This study has shown that PHE and hematoma volumes are intimately related to each other, with an increase in the former from baseline to 24 hours being significantly associated with volumes of the underlying hematoma at baseline and in the degree of its growth. Clinical severity defined by National Institutes of Health stroke scale scores, time from ICH onset to baseline CT, location of hematoma, and the use of mannitol also independently predicted the growth of PHE. However, growth of PHE was significantly associated with risk of poor outcome, defined by death or dependency at 90 days, after adjustment for various prognostic factors, including demography, comorbid cardiovascular risk factors, aspects of management, time to diagnosis, clinical severity and profile, hematoma growth, and randomized treatment. Moreover, the stronger association of PHE and outcome in the guideline group, and less growth of PHE in the intensive group, suggest an effect of early intensive BP-lowering on PHE.
Our analysis included a large number of patients (n=1138) with CT-confirmed ICH who were assessed within 6 hours of onset and prospectively followed up and with standardized measures. We have confirmed findings from previous observational studies 5, 6, 14 and INTERACT1, 12 , which indicate that initial PHE develops within a few hours after the onset of ICH. 12 In multivariable analyses, baseline hematoma volume and 24-hour hematoma growth were independently associated with the growth of the volume of PHE. Although we confirmed the prognostic importance of the underlying hematoma volume, 12 ,21 the findings also indicate that the PHE is important in its own right where potential mechanisms-hydrostatic pressure and clot retraction-may be amendable to treatment. 9, 22 Data are conflicting about the independent significance of PHE on clinical outcomes. Some 23, 24 but not all 12, 17, 22 observational studies have shown a relationship between PHE and clinical outcome. The discrepancy between previous studies may be attributable to selection bias and sample size, which to some extent was addressed in the present analysis, although may still have affected our ability to determine an association on the separate components of death and major disability in the primary outcome. Other strengths of the study include the prospective assessment of patients early after the onset of ICH and the quantitative assessment of CT hematoma parameters. We recognize that, however, there are some limitations that include an evaluation of PHE growth only in the first 24 hours after the onset of ICH. PHE is recognized to increase in volume beyond this time point, reaching a peak in growth after at least several days, and sometimes a few weeks, in some patients. 6, 14, 21 Thus, we may have underestimated the association of PHE on clinical outcomes. Moreover, as the INTERACT studies excluded patients with more severe ICH who were likely to die early on the basis of clinical or radiological criteria, the present findings may not be applicable to cases with severe ICH.
In summary, growth in PHE has independent prognostic significance in acute ICH. Strategies to attenuate PHE growth may improve recovery from this major illness.
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